MET Mutation Associated with Responsiveness to Crizotinib.
作者信息
Waqar Saiama N, Morgensztern Daniel, Sehn Jennifer
机构信息
Division of Medical Oncology, Department of Internal Medicine, Washington University, School of Medicine, St. Louis, MO.
Division of Medical Oncology, Department of Internal Medicine, Washington University, School of Medicine, St. Louis, MO.
出版信息
J Thorac Oncol. 2015 May;10(5):e29-e31. doi: 10.1097/JTO.0000000000000478.
Abstract
摘要
相似文献
1
MET Mutation Associated with Responsiveness to Crizotinib.与克唑替尼反应性相关的MET突变
J Thorac Oncol. 2015 May;10(5):e29-e31. doi: 10.1097/JTO.0000000000000478.
2
MET-Mutated NSCLC with Major Response to Crizotinib.对克唑替尼有显著反应的MET突变型非小细胞肺癌
J Thorac Oncol. 2015 May;10(5):e33-e34. doi: 10.1097/JTO.0000000000000491.
3
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.一例携带MET剪接位点突变的肺腺癌患者对克唑替尼的反应
Clin Lung Cancer. 2015 Sep;16(5):e101-4. doi: 10.1016/j.cllc.2015.01.009. Epub 2015 Feb 7.
4
Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification.一名患有携带c-MET扩增的肺腺癌患者对克唑替尼完全缓解。
J BUON. 2017 Jan-Feb;22(1):279-280.
5
Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.获得性表皮生长因子受体（EGFR）突变作为MET突变肿瘤中克唑替尼潜在的耐药驱动因素。
J Thorac Oncol. 2016 Feb;11(2):e21-3. doi: 10.1016/j.jtho.2015.08.001. Epub 2015 Dec 18.
6
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.一名从未吸烟的肺腺癌患者，存在MET外显子14突变（D1028N），接受克唑替尼治疗后出现快速部分缓解。
Invest New Drugs. 2016 Jun;34(3):397-8. doi: 10.1007/s10637-016-0332-0. Epub 2016 Feb 18.
7
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.通过综合基因组分析检测具有MET、ALK和ROS1基因组改变的克唑替尼敏感型肺腺癌
Clin Lung Cancer. 2015 Sep;16(5):e105-9. doi: 10.1016/j.cllc.2015.03.002. Epub 2015 Mar 25.
8
Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.一名体能状态较差且患有晚期MET外显子14跳跃突变阳性肺腺癌的患者对克唑替尼的拉扎勒斯型反应
J Thorac Oncol. 2016 Jul;11(7):e81-2. doi: 10.1016/j.jtho.2016.01.017. Epub 2016 Feb 1.
9
[Interest of crizotinib in a lung cancer patient with de novo amplification of MET].克唑替尼对一名MET基因发生新发扩增的肺癌患者的疗效
Rev Mal Respir. 2017 Jan;34(1):57-60. doi: 10.1016/j.rmr.2016.05.007. Epub 2016 Oct 13.
10
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.对吉非替尼耐药但对克唑替尼敏感的肺腺癌患者，同时存在表皮生长因子受体罕见突变（L861Q）以及ALK/MET/ROS1基因拷贝数增加。
J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37.
引用本文的文献
1
Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications.靶向癌症中的c-MET改变：遗传驱动因素与治疗意义综述
Cancers (Basel). 2025 Apr 29;17(9):1493. doi: 10.3390/cancers17091493.
2
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer.受体酪氨酸激酶MET作为非小细胞肺癌治疗靶点的作用不断扩展。
Cell Rep Med. 2025 Mar 18;6(3):101983. doi: 10.1016/j.xcrm.2025.101983. Epub 2025 Feb 27.
3
Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment.揭示 HGF/c-Met 信号在非小细胞肺癌肿瘤微环境中的作用。
Int J Mol Sci. 2024 Aug 22;25(16):9101. doi: 10.3390/ijms25169101.
4
Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic V600EMT colon cancer patient with acquired amplification and fusion: a case report.一例伴有获得性扩增和融合的转移性V600EMT结肠癌患者对克唑替尼+瑞戈非尼+PD-1抑制剂的部分反应：病例报告
AME Case Rep. 2024 Apr 1;8:38. doi: 10.21037/acr-23-155. eCollection 2024.
5
The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy.MET原癌基因：对驱动恶性肿瘤的分子机制三十年的洞察
Pharmaceuticals (Basel). 2024 Mar 30;17(4):448. doi: 10.3390/ph17040448.
6
Recording and classifying MET receptor mutations in cancers.记录和分类癌症中的MET受体突变。
Elife. 2024 Apr 23;13:e92762. doi: 10.7554/eLife.92762.
7
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.非小细胞肺癌（NSCLC）中的MET：走过“漫长而曲折的道路”寻找靶点。
Cancers (Basel). 2023 Sep 28;15(19):4779. doi: 10.3390/cancers15194779.
8
Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?针对非小细胞肺癌（NSCLC）中的 MET：新的老故事？
Int J Mol Sci. 2023 Jun 14;24(12):10119. doi: 10.3390/ijms241210119.
9
Comprehensive analysis of mutations in NSCLC patients in a real-world setting.对真实世界中NSCLC患者的突变进行综合分析。
Ther Adv Med Oncol. 2022 Jul 16;14:17588359221112474. doi: 10.1177/17588359221112474. eCollection 2022.
10
Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art.肺肉瘤样癌的多模态治疗：当前技术水平综述
J Oncol. 2022 Mar 25;2022:8541157. doi: 10.1155/2022/8541157. eCollection 2022.
本文引用的文献
1
Diagnostic utility of targeted next-generation sequencing in problematic cases.靶向下一代测序在疑难病例中的诊断效用。
Am J Surg Pathol. 2014 Apr;38(4):534-41. doi: 10.1097/PAS.0000000000000161.
2
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.利用 cBioPortal 进行复杂癌症基因组学和临床特征的综合分析
Sci Signal. 2013 Apr 2;6(269):pl1. doi: 10.1126/scisignal.2004088.
3
Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.胃癌细胞系 Hs746T 存在 c-Met 剪接位点突变，导致跨膜结构域缺失。
Biochem Biophys Res Commun. 2010 Apr 16;394(4):1042-6. doi: 10.1016/j.bbrc.2010.03.120. Epub 2010 Mar 21.
4
Ethnic differences and functional analysis of MET mutations in lung cancer.肺癌中 MET 突变的种族差异和功能分析。
Clin Cancer Res. 2009 Sep 15;15(18):5714-23. doi: 10.1158/1078-0432.CCR-09-0070. Epub 2009 Sep 1.
5
Somatic mutations lead to an oncogenic deletion of met in lung cancer.体细胞突变导致肺癌中met基因的致癌性缺失。
Cancer Res. 2006 Jan 1;66(1):283-9. doi: 10.1158/0008-5472.CAN-05-2749.
Zotero 插件